Inspire, Faes deal
FAE granted ISPH an exclusive license in the U.S. and Canada to develop and commercialize oral bilastine to treat or
Gathering data...
FAE granted ISPH an exclusive license in the U.S. and Canada to develop and commercialize oral bilastine to treat or